191 – Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System
Background Long-acting cabotegravir (CAB-LA) was approved as HIV preexposure prophylaxis (PrEP) in the U.S. in December 2021, but data are limited on use in clinical practice. We evaluated CAB-LA uptake and persistence in an integrated healthcare system and compared early CAB-LA adopters to individuals dispensed oral PrEP only. Methods We extracted electronic health records of…